Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ARCA BIOPHARMA, INC.

(ABIO)
Delayed Nasdaq  -  03:58:30 2023-01-27 pm EST
2.220 USD   -2.20%
2022Arca Biopharma, Inc. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
2022James Flynn Joins ARCA biopharma Board of Directors
AQ
2022ARCA biopharma, Inc. Appoints James Flynn to Board of Directors
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ARCA biopharma : Shareholder Director Nominations - Form 8-K

10/20/2022 | 05:20pm EST
abio-8k_20221020.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2022

ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

000-22873

36-3855489

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

10170 Church Ranch Way, Suite 100, Westminster, CO

80021

(Address of Principal Executive Offices)

(Zip Code)

Registrant's Telephone Number, Including Area Code: (720) 940-2200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

ABIO

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.08.

Shareholder Director Nominations.

On October 20, 2022, the board of directors (the "Board") of ARCA biopharma, Inc., a Delaware corporation (the "Company"), approved December 15, 2022 as the date of the Company's 2022 Annual Meeting of Stockholders (the "Annual Meeting"). The Board also approved October 25, 2022 as the record date for stockholders entitled to notice of and to vote at the Annual Meeting. Due to the fact that the Annual Meeting will be held more than 30 calendar days from the date of the Company's 2021 Annual Meeting of Stockholders, the due dates for the provision of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities and Exchange Commission (the "SEC") and the bylaws of the Company listed in the Company's 2021 Proxy Statement on Schedule 14A as filed with the SEC on April 21, 2021 are no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, are now due to the Company no later than October 24, 2022. The Company currently intends to make its proxy materials available beginning on or about November 4, 2022.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

104

Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 20, 2022

ARCA biopharma, Inc.

(Registrant)

By:

/s/ C. Jeffrey Dekker

Name:

C. Jeffrey Dekker

Title:

Chief Financial Officer

Disclaimer

ARCA biopharma Inc. published this content on 20 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2022 21:19:05 UTC.


ę Publicnow 2022
All news about ARCA BIOPHARMA, INC.
2022Arca Biopharma, Inc. : Change in Directors or Principal Officers, Submission of Matters to..
AQ
2022James Flynn Joins ARCA biopharma Board of Directors
AQ
2022ARCA biopharma, Inc. Appoints James Flynn to Board of Directors
CI
2022Arca Biopharma, Inc. : Change in Directors or Principal Officers, Financial Statements and..
AQ
2022ARCA biopharma announces Third Quarter 2022 Financial Results
AQ
2022Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q3 Loss $-0.16
MT
2022ARCA biopharma Announces Third Quarter 2022 Financial Results
AQ
2022ARCA BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
2022ARCA biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months End..
CI
2022Arca Biopharma : Shareholder Director Nominations - Form 8-K
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -19,3 M - -
Net cash 2021 52,9 M - -
P/E ratio 2021 -1,55x
Yield 2021 -
Capitalization 32,0 M 32,0 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 18
Free-Float 99,3%
Chart ARCA BIOPHARMA, INC.
Duration : Period :
ARCA biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARCA BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
Michael R. Bristow President, Chief Executive Officer & Director
C. Jeffrey Dekker Chief Financial Officer
Robert E. Conway Chairman
Debra Marshall Chief Medical Officer
Thomas A. Keuer Executive Vice President-Pharmaceutical Operations
Sector and Competitors
1st jan.Capi. (M$)
ARCA BIOPHARMA, INC.-6.33%32
VERTEX PHARMACEUTICALS11.16%82 403
REGENERON PHARMACEUTICALS, INC.2.88%79 279
WUXI APPTEC CO., LTD.20.37%42 325
BIONTECH SE-5.11%34 640
BEIGENE, LTD.18.96%27 198